Effective against acne: tpSkin for easy support of skin health

Garching near Munich, May 12, 2023 – ESA has given the green light for the latest research project of terraplasma, the innovation leader in the development and implementation of applications with   cold   atmospheric plasma (Cold Plasma for short).  As part of the ESA Spark Funding program, the company received support for the development  of a device that uses a new, specially designed coldplasma  to provide an effective and sustainable treatment of acne  and other skin diseases and irritations.

Acne – widespread skin condition of youth

With a probability of occurrence of almost 100 percent, acne is the number one skin infection in adolescence and puberty. While a majority  of 60  percent  of  cases are mild acne that can be treated with non-prescription drugs, the remaining 40 percent are  acute or even chronic cases that require medical attention. The latter type of acne often presents a therapeutic challenge, as it is associated with acute lesions (destroyed cell tissue), severe inflammation and rapid scarring. In addition, patients with acne often suffer from low self-esteem, reduced quality of life and depression.

Cost factor acne-prone skin

In addition to this dermatological and psychological burden, acne also puts a financial strain on patients. An individual acne treatment (this only includes acne products but no professional medical care) costs about € 1,000 per year. On the other hand, the costs charged to the healthcare provider average €690 (up to €870) per acute acne period, including inpatient stays, outpatient services, emergency care and pharmacy costs during the episode.

Cold plasma against hard-to-reach acne bacteria

Acne infections are mainly caused by the anaerobic bacterium Cutibacterium acnes. Therefore, the device developed by terraplasma  will produce cold plasma, which  is able to efficiently inactivate these bacteria, which are mainly found in follicles and pores (and are therefore difficult to reach with creams and liquids), without damaging the surrounding healthy tissues.

Cold plasma makes the skin open to creams, medications and healing

Another goal is to design the cold plasma in such a way that it improves the absorption of antibacterial creams and liquids and is effective against other skin diseases and irritations.    Initial preliminary investigations have shown very positive results when using cold plasma on the skin: on the one hand, the cold plasma ensures that the regeneration of the skin cells is stimulated and, on the other hand, the skin pores are opened – this means that creams, but also externally administered medications can be better absorbed.

Ambitious goals with successful signs

In order to achieve all these goals, terraplasma will build  on  the extensive practical knowledge already gained by the company in the development of the successful  plasma care® for professional wound treatment and plasma derma care®® for the professional treatment of skin diseases.

As part of the funding program, the new  device from terraplasma (working title tpSkin) will be developed primarily for use by end users with the following core properties:

  • Transferable: no cables or hoses and battery operation with charging by induction
  • Practical: small, handy and can be used in one-handed operation
  • Simple: uncomplicated operation by medical laymen possible
  • kompakt: Use of new low-line plasma source based on SMD (Surface Micro-Discharge) technology
  • Innovative: newly developed, bactericidal plasma, which is gentle on the tissue in addition to combating acne and improves cream absorption
  • Tenable: only air and electricity are needed for plasma production

Terraplasma is confident that it will be able to intensively test the new device with  the first prototypes at the end of the year  as part of this funding program. Special attention is also paid to the compact size and cost of the device, which should be convincing in commercial form – terraplasma is still looking for a partner for marketing – not only because of its effectiveness.

tpSkin 003
tpSkin 002
Press release

terraplasma receives U.S. patent for Plasma Activated Water (PAW)

U.S. patent granted to terraplasma, the innovation leader in the development and implementation of cold atmospheric plasma (cold plasma for short) applications. The United States Trademark and Patent Office (USTPO) granted a patent under the number US 11,628,050B2 for the “Apparatus and method for treating objects, in particular teeth and dentures”. The invention relates in detail to a device and method for treating, in particular cleaning objects (in particular dental objects and/or teeth) with so-called “Plasma Activated Water (PAW)”.

Read more »
Press release

Start of research project on surface disinfection

Garching near Munich, April 25, 2023 – Clean start at terraplasma, the innovation leader in the field of development and implementation of applications with cold atmospheric plasma (Cold Plasma for short). Representatives of the Chair for Medical Technology Materials and Implants at the Technical University of Munich and terraplasma met on the joint research project “Plasma-activated mist for disinfecting surfaces” that started on April 17th at the company’s premises in Garching near Munich. The first personal kick-off meeting took place under the motto “plasmaTOP – disinfect surfaces without chemicals or heat”.

Read more »

Subscribe to our newsletter

Do not miss any more news about Cold Plasma
and subscribe to our newsletter.